Immunic, Inc. (NASDAQ:IMUX) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET

Company Participants

Jessica Breu - Head of IR & Communications

Daniel Vitt - CEO and President

Glenn Whaley - CFO

Conference Call Participants

Lauren Timmins - Piper Sandler

Andreas Argyrides - Wedbush

Matt Kaplan - Ladenberg

Operator

Good morning, and welcome to Immunic's Second Quarter 2023 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today's call.

Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer and President; as well as Glenn Whaley, our Chief Financial Officer. Please note that all participants will be in listen only mode and this event is being recorded. [Operator Instructions].

Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate, or words with similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunic's actual results to differ materially from those discussed here.

Please note that these forward-looking statements reflect the Immunic's opinions only as of the date of this presentation, and it undertakes no obligation to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Please refer to Immunic's SEC filings for a more detailed description of the risk factors that may affect Immunic's results and these forward-looking statements.

I would now like to turn the call over to our CEO and President, Dr. Daniel Vitt, to begin the presentation.

Daniel Vitt

Yes. Thank you, Jessica. I would also like to welcome everybody to Immunic's second quarter 2023 earnings call. Earlier this morning, we announced our financial results for the second quarter ended June 30, 2023, and highlighted recent activities as well as upcoming milestones.

During today's call, we will walk through our second quarter 2023 and subsequent highlights, financial and operating results as well as anticipated upcoming milestones. After the presentation, as Jessica noted, we will open the line to give the audience an opportunity to ask questions.

Let's start with a review of our second quarter 2023 and subsequent highlights. In April, we reported positive data from the maintenance phase of our Phase IIb CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe ulcerative colitis. These results were extremely encouraging as they demonstrated statistically significant activity of vidofludimus Calcium as compared to placebo, while confirming the very favorable safety and tolerability profile for the drug already observed in other trials.